Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is experiencing significant share price momentum, with a 37% increase in 2026 so far, despite facing regulatory challenges related to its schizophrenia treatment, brilaroxazine [2][3]. Group 1: Share Price Performance - Reviva Pharmaceuticals Holdings, Inc. has surged approximately 37% in 2026 as of January 9, showcasing strong share price momentum [2]. Group 2: Regulatory Challenges - The FDA has recommended a second Phase 3 trial for brilaroxazine in schizophrenia, which presents near-term regulatory challenges for the company [3]. - H.C. Wainwright has reiterated a 'Buy' rating with a price target of $4, projecting regulatory submission in late 2027 and potential approval in late 2028 [3]. Group 3: Analyst Ratings and Price Targets - Roth Capital has reduced its price target for Reviva Pharmaceuticals to $1.50 while maintaining a 'Buy' rating, citing anticipated equity dilution of $60-75 million needed for the second Phase 3 study [4]. - Despite the adjustment, Roth Capital remains optimistic about the therapeutic potential of brilaroxazine [4]. Group 4: Clinical Development Updates - Reviva Pharmaceuticals provided an update on the publication of vocal biomarker findings from the RECOVER trial, reinforcing the efficacy assessment of brilaroxazine for negative symptoms [5]. - The company is advancing its RP5063 (brilaroxazine) and RP1208 pipelines, focusing on developing therapies for CNS, respiratory, and metabolic conditions [6].

CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Sachs 9th Annual Neuroscience Innovation Forum, taking place January 11, 2026, in San Fran ...

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will present findings on the anti-inflammatory effects of brilaroxazine from the Phase 3 RECOVER trial at the 2025 Neuroscience meeting [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has secured composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [3]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases [1][4] - The company will be represented by its Founder, President, and CEO, Laxminarayan Bhat, at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025, in New York City [1] Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [4] - The company has been granted composition of matter patents for both drug candidates in the United States, Europe, and several other countries [4] Conference Details - The Spartan Capital Securities conference will feature over 60 selected companies across various sectors, including technology, healthcare, and consumer [2] - More than 500 institutional and high-net-worth investors are expected to attend, providing opportunities for dialogue between growth companies and the investment community [2]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will present negative symptom data for brilaroxazine from the Phase 3 RECOVER trial at the CNS Summit 2025 [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has secured composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries [3]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][4] - The company will participate in a fireside chat and KOL webinar on October 10, 2025, featuring discussions on schizophrenia treatment and clinical data for its lead drug candidate, brilaroxazine [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [4] - The company has secured composition of matter patents for both drug candidates in the United States, Europe, and several other countries [4]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will participate in the 4th Annual Roth Healthcare Opportunities Conference on October 9, 2025, where its CEO will engage in a panel discussion and host one-on-one investor meetings [1][2] Company Overview - Reviva's current pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has secured composition of matter patents for both drug candidates in the United States, Europe, and several other countries [3]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will present and host one-on-one investor meetings at the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has been granted composition of matter patents for both drug candidates in the United States, Europe, and several other countries [3]

Core Viewpoint - Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of 27 million shares of common stock and associated warrants, aiming to raise approximately $9 million to fund research and development and for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 27,000,000 shares of common stock and Series E and Series F warrants, priced at $0.335 per share, with total gross proceeds expected to be around $9 million before expenses [1][3]. - The Series E Warrants and Series F Warrants will have an exercise price of $0.335 per share, with Series E Warrants expiring in five years and Series F Warrants expiring in 12 months [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to support research and development activities, working capital, and other general corporate purposes [3]. Group 3: Company Overview - Reviva is a late-stage biopharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases, with a pipeline that includes two drug candidates, brilaroxazine (RP5063) and RP1208 [6].

Core Insights - Reviva Pharmaceuticals is advancing its brilaroxazine program towards potential registration, with a planned meeting with the FDA in Q4 2025 to discuss the New Drug Application (NDA) submission targeted for Q2 2026 [2][5] Clinical Program and Business Highlights - The company successfully completed a 1-year open-label extension (OLE) trial for brilaroxazine, demonstrating a well-tolerated safety profile and robust broad-spectrum efficacy across all symptom domains in schizophrenia [1][5] - Brilaroxazine showed a significant reduction in PANSS total score by 18.1, positive symptoms by 5.0, and negative symptoms by 4.4, with a discontinuation rate of 35% after 1 year [5] - Reviva is expanding its patent portfolio, aiming for potential patent and market exclusivity up to 2045 and beyond [5] - A late-breaking poster presentation on the RECOVER 12-month OLE trial was presented at the 2025 ASCP annual meeting [5] Financial Results - For the second quarter ended June 30, 2025, the company reported a net loss of approximately $6.1 million, or $0.12 per share, compared to a net loss of approximately $7.9 million, or $0.26 per share, for the same period in 2024 [10][13] - As of June 30, 2025, cash and cash equivalents totaled approximately $10.4 million, down from approximately $13.5 million as of December 31, 2024 [10][11] Anticipated Milestones and Events - The company plans to initiate a potential registrational Phase 3 RECOVER-2 trial for brilaroxazine pending FDA recommendations [5] - An IND submission for a liposomal-gel formulation of brilaroxazine in psoriasis is expected by Q2 2026 [10]